The articles selected for CME courses in the June and July issues did not include all of the author’s disclosure statements because of an inadvertent omission during the Journal’s production. The authors had previously disclosed all conflicting interests, as requested. Authors whose disclosure data were not published are presented here.
Omega-3 Fatty Acids and Mood Disorders (Am J Psychiatry 2006; 163:969–978): Dr. Parker reports receiving payment for lectures and chairing and membership of Advisory Boards for several Australian pharmaceutical companies. Dr. Hadzi-Pavlovic reports a relationship with Eli Lilly involving a lecture to psychiatry trainees on statistics. Drs. Gibson, Brotchie, Heruc, and Rees report no competing interests.
APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.